The Efficacy and Safety of Apatinib Combined With Etoposide in Heavily Pretreated Advanced Non-small Cell Lung Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-03-31

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The development of anti-angiogenesis drugs has led to renewed enthusiasm in lung cancer treatments. Apatinib is a tyrosine kinase inhibitor which selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR-2). Etoposide is an oral preparation for lung cancer which is recommended by NCCN guideline. The investigators wondered whether these two drugs have synergistic effects when treating advanced non-small cell lung cancer patients who failed to previous at least 2nd line treatments. Thus, the aim of this trial is to investigate the efficacy and safety of apatinib combined with etoposide in heavily pretreated advanced non-small cell lung cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer

NCT01270386

Non-Small-Cell Lung Cancer

COMPLETED PHASE2

Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer

NCT02980809

Small Cell Lung Cancer

UNKNOWN PHASE2

Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC

NCT03201146

Lung Cancer Non Small Cell Lung Cancer Combination Chemotherapy +1 more

UNKNOWN PHASE1/PHASE2

The Efficacy and Safety of Apatinib in Heavily Pretreated Advanced Non-squamous Non-small Cell Lung Cancer

NCT02515435

Non-Small Cell Lung Cancer

UNKNOWN PHASE2

Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer

NCT03461185

Non Small Cell Lung Cancer

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Apatinib+Etoposide

Apatinib combined with Etoposide

Group Type OTHER

Apatinib

Intervention Type DRUG

Apatinib, 250mg daily, po, continue until disease progression

Etoposide

Intervention Type DRUG

Etoposide, 50mg daily, po, day 1 to day 20, repeat Q 4 weeks until disease progression

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Apatinib

Apatinib, 250mg daily, po, continue until disease progression

Intervention Type DRUG

Etoposide

Etoposide, 50mg daily, po, day 1 to day 20, repeat Q 4 weeks until disease progression

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

VP-16

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Obtain of informed consent.
* Histologically or cytologically confirmed non-small cell lung cancer.
* World Health Organization (WHO) performance status (PS) of 0 to 2.
* Measurable lesions as defined by RECIST criteria.
* Second-line or more treatments.
* Wild type of epidermal-growth-factor receptor (EGFR).
* Life expectancy ≥12 weeks.
* Organ functions normal, as defined below, within two weeks of randomization:

• Hb≥90g/L Absolute neutrophils count(ANC)≥1.5×109/L Platelets≥80×109/L Serum bilirubin≤2×ULN; Aspartate transaminase(AST) and alanine transaminase (ALT)≤2.5×ULN(≤5×ULN if liver metastases) Creatinine clearance≥45ml/min or Cr≤1.25×ULN.
* Females of child-bearing potential must have negative serum pregnancy test.
* Sexually active males and females (of childbearing potential) willing to practice contraception during the study.

Exclusion Criteria

* Small cell lung cancer.
* Newly diagnosed Central Nervous System (CNS) metastases that have not yet been definitively treated with surgery and/or radiation.
* Uncontrolled hypertension.
* Myocardial ischemia or infarction more than stage II, cardiac insufficiency.
* Abnormal coagulation (INR\>1.5 or PT\>ULN+4, or APTT\>1.5 ULN), bleeding tendency or receiving coagulation therapy.
* Difficulties in taking pills (inability to swallow tablets,GI tract resection, chronic bacillary diarrhea and intestinal obstruction).
* Hemoptysis, more than 2.5ml daily.
* Thrombosis in 12 months, including pulmonary thrombosis, stoke, or deep venous thrombosis.
* Unhealed bone fracture or wound for long time.
* Received big surgery, had bone fracture or ulcer in 4 weeks.
* Urine protein≥++, or urine protein in 24 hours≥1.0g.
* Pregnant or lactating woman.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No